company background image
DXB

Dimerix ASX:DXB Stock Report

Last Price

AU$0.17

Market Cap

AU$54.5m

7D

9.7%

1Y

-29.2%

Updated

01 Dec, 2022

Data

Company Financials
DXB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

DXB Stock Overview

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs.

Dimerix Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Dimerix
Historical stock prices
Current Share PriceAU$0.17
52 Week HighAU$0.29
52 Week LowAU$0.12
Beta1.11
1 Month Change6.25%
3 Month Change9.68%
1 Year Change-29.17%
3 Year Change36.00%
5 Year Change36.00%
Change since IPO-15.00%

Recent News & Updates

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Sep 16
We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Recent updates

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Sep 16
We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Jun 02
We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Sep 20
Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

May 17
Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Feb 01
Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Shareholder Returns

DXBAU BiotechsAU Market
7D9.7%0.4%0.5%
1Y-29.2%-4.4%-2.0%

Return vs Industry: DXB underperformed the Australian Biotechs industry which returned -4.4% over the past year.

Return vs Market: DXB underperformed the Australian Market which returned -2% over the past year.

Price Volatility

Is DXB's price volatile compared to industry and market?
DXB volatility
DXB Average Weekly Movement11.4%
Biotechs Industry Average Movement8.9%
Market Average Movement9.0%
10% most volatile stocks in AU Market16.0%
10% least volatile stocks in AU Market4.1%

Stable Share Price: DXB is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: DXB's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aNina Websterhttps://dimerix.com

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease. The company is headquartered in Fitzroy, Australia.

Dimerix Limited Fundamentals Summary

How do Dimerix's earnings and revenue compare to its market cap?
DXB fundamental statistics
Market CapAU$54.55m
Earnings (TTM)-AU$10.49m
Revenue (TTM)AU$6.47m

8.4x

P/S Ratio

-5.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DXB income statement (TTM)
RevenueAU$6.47m
Cost of RevenueAU$0
Gross ProfitAU$6.47m
Other ExpensesAU$16.96m
Earnings-AU$10.49m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.033
Gross Margin100.00%
Net Profit Margin-162.25%
Debt/Equity Ratio0%

How did DXB perform over the long term?

See historical performance and comparison